NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Organon securities ...

公司动态 - 律师事务所Faruqi & Faruqi正在调查Organon & Co（NYSE: OGN）的潜在证券索赔案件 并提醒投资者在2025年7月22日前申请成为集体诉讼的首席原告 [3] - Organon被指控在资本分配策略上向投资者提供虚假和误导性陈述 包括隐瞒债务削减策略的优先级 导致季度股息减少70% [5] - 公司股价在2025年4月30日至5月1日期间从每股12.93美元暴跌至9.45美元 单日跌幅超过27% [6] 法律行动 - 损失超过75,000美元的投资者可直接联系Faruqi & Faruqi合伙人Josh Wilson讨论法律权利 [1] - 律师事务所自1995年成立以来已为投资者追回数亿美元资金 在纽约、宾夕法尼亚等地设有办公室 [4] - 潜在集体诉讼成员可选择通过自选律师担任首席原告 或保持缺席成员身份 但不影响赔偿权益 [7][8] 信息披露 - Organon被指控在强调季度股息为"第一资本分配优先级"的同时 隐瞒收购Dermavant后债务削减策略对股息的重大影响 [5] - 律师事务所呼吁知情者（包括举报人、前员工等）提供与Organon行为相关的信息 [8] - 案件详情可通过律师事务所官网或社交媒体渠道获取 [9]

SAN DIEGO, May 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investi ...

SAN DIEGO, May 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action la ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Act of 1934.If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v. Organon & Co., et al. (Case No. 2:25-cv-05322) has been commenced in the United States District Court for the District of New Jersey ...

SAN DIEGO, May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more ...

We initiate (NYSE: NYSE: OGN ) at Strong Buy w/ $26.4 PT. Organon & Co. is a diversified portfolio of Rx therapies anchored by global leadership in women's health and accelerating biosimilars. Our thesis is supported by a forecasted operational inflection , withMoretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with d ...

SAN DIEGO, May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can pr ...